Acrongenomics Inc. Explores Novel 'Nanoweapons' in Eliminating Hospital-Related Infections.

CALGARY, Alberta -- Acrongenomics, Inc. (OTCBB:AGNM) is pleased to announce that it is currently under negotiations in order to complete a collaboration agreement with an International group of experts towards the development of unique "nanoweapons" that exhibit extraordinary properties in eliminating hospital related infections.

Hospital related infections are a major cause of morbidity and mortality around the world. The pathogenesis of hospital-related infections is quite complicated, the virulence of the pathogens is variable, and the host factors have not yet been well defined.

Hospital related infections are one of the 10 leading causes of mortality in developed countries. They often involve bacteria which are resistant to antibiotics, thereby complicating their treatment. Infections involving multi-drug resistant bacteria are a major concern for most hospitals and healthcare establishments, since they contribute to an increase in morbidity and mortality compared to the underlying diseases alone. They also impact the length of stay and the related healthcare costs.

According to the U.S. Centers for Disease Control (CDC) and Prevention, hospital related infections are the fourth leading cause of death in the United States, after heart disease, cancer and stroke.

Among hospital related infections, those caused by Methicillin-resistant Staphylococcus aureus (MRSA) cause particular concern, since they are associated with high morbidity and mortality and are a significant burden on healthcare resources (Clin Infect Dis. 2003). Most frequently cross-transmitted between hospitalized patients through healthcare workers, MRSA is highly contagious and responsible for endemic infections which are very difficult to control.

Antimicrobial resistant infections in healthcare settings are a major threat to patient safety. Each year in the United States an estimated 2 million hospitalized people acquire infections that result in more than 90,000 deaths. More than half of these infections are caused by bacteria that are resistant to at least one of the antimicrobials commonly used to treat those infections, according to CDC.

There are many ways for the infections to spread, from the hands of health care workers, doctors, nurses, nursing aides, and technicians to the patients they encounter. The skin in healthy people provides an every day barrier against germs. But this barrier is routinely breached in hospitals because the skin is opened for operations, because of wounds, and because of the presence of indwelling medical devices such as intravenous catheters or urinary catheters.

Antibiotic resistant infectious diseases impose a significant burden on society, and surpass $30 billion in annual direct treatment costs in the U.S. alone. The high cost stems from several key factors such as: Individuals infected with drug resistant organisms usually have a poor prognosis and are more likely to require hospitalization and drug-resistant infections acquired in hospitals nearly triple the cost of hospital stays. The cost of antibiotic resistance is expected to grow larger as medical experts anticipate record increases of antibacterial resistance in the next decade.

Acrongenomics Inc. strongly believes that such a joint proposal, once adopted would fulfill all current unmet needs in such a thriving market.

Acrongenomics, Inc. also announced today the appointment of Mr. Constantine Poulios, LL.M., as President. Mr. Poulios was holding the position of Vice President at Acrongenomics Inc. as of July 6, 2004. Mr. Poulios succeeds Dr. Eleftherios Georgakopoulos, who retired from the board earlier this week. The leadership change coincides with the transfer of the former president's 4 million shares to the treasury of the company, while the company keeps full title on all its technology developed to date.

Mr. Poulios has extensive experience in serving multinational companies. An attorney by education and profession, he was part of the Corporate and Tax Advisory Services of Ernst & Young before joining Acrongenomics, Inc. Mr. Poulios was managing important accounts including that of Coca Cola, Halliburton, Hewlett Packard, ABN AMRO, Citigroup, Ciments Francais, Pfizer, GlaxoSmithKline and EMI Music for Ernst & Young Southeast Europe, while he has also worked for Ernst & Young in the US. He obtained his Master's of Laws from Northwestern University School of Law in Chicago in 1997, while he is a 1995 graduate from the School of Law at the National University of Athens. Mr. Poulios has also been awarded with a Certificate in Law in 1993 from the School of Law at the University of Bordeaux in France and he has attended graduate courses in management in US universities.

As a corporate executive who has driven business initiative of global corporations for some years, Mr. Poulios is looking forward to bringing in apart from his leadership skills and his business and legal expertise, hands-on knowledge on how to properly conduct business in the rigorous environment of the Sarbanes-Oxley legislation.

Acrongenomics, Inc. also announced today the appointment of Mr. Platon Tzouvalis, MSc., as Vice President. As a Biochemist, Mr. Tzouvalis is an experienced pharmaceutical industry professional. He has been a member of Acrongenomics' Scientific Advisory Board since May 2004. His expertise lies in the areas of Quality Control, Operational Procedures as well as Pharmaceutical Product and Process Improvement. He received his B.S. Degree in Biochemistry from the University of Illinois in 1990 and his Master's Degree in the same field from DePaul University at Chicago in 1995.

Mr. Tzouvalis' earlier career includes working as a Research Chemist in collaboration with the University of Illinois at Chicago, holding the position of Research and Development Chemist at SynQuest, Inc. and as Advanced Quality Assurance Specialist of Organic Operations and then Project Manager in Bioanalytical Quality Assurance for Abbott Laboratories. Mr. Tzouvalis has also been awarded with the Abbott Diagnostics Division Science Award of 2002 as part of the Organic Operation Remediation Team.

Acrongenomics, Inc. is a research & development nanobiotechnology company pioneering uniquely advanced nanobiotechnology applications for the Medical Community.